Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06235866
Other study ID # 20230922
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date February 1, 2023
Est. completion date November 1, 2025

Study information

Verified date May 2024
Source Wuhan Central Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators retrospectively analyze the clinical characteristics of severe COVID-19 in our hospital, and then establish a prediction model for long-term complications in patients with severe COVID-19, and strengthen follow-up to improve the prognosis of patients.


Description:

At present, there is a lack of prediction models for the long-term complications of severe COVID-19. Therefore, the investigators used the hospital big data platform to retrospectively analyze the clinical characteristics of severe COVID-19 in our hospital, and conducted cohort follow-up of the changes in lung function including FEV1, FVC,FEV1% and DLCO, etc and and high-resolution CT of patients after discharge. COX model and other statistical methods were used to establish a prediction model for long-term complications of severe COVID-19, and early identification and intervention, strengthen follow-up, and improve the prognosis of patients.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 500
Est. completion date November 1, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: The patient met the diagnostic criteria for severe COVID-19 Exclusion Criteria: - Pregnant women Patients who died of COVID-19 Patients younger than 18 years of age without pulmonary CT

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pulmonary rehabilitation
According to the pulmonary rehabilitation guidelines, patients with severe COVID-19 were given regular rehabilitation treatment, including breathing exercises and physical rehabilitation exercises.

Locations

Country Name City State
China Follow-up of patients with severe COVID-19 Wuhan

Sponsors (1)

Lead Sponsor Collaborator
Wuhan Central Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lung function Pulmonary function indicators improved gradually 1 year
Primary Imaging of the lung The residual lesions in the lung were gradually absorbed 1 year
See also
  Status Clinical Trial Phase
Completed NCT05175833 - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19 Phase 2
Recruiting NCT05256511 - COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Completed NCT04866082 - Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
Active, not recruiting NCT04918901 - Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
Recruiting NCT05233605 - Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Not yet recruiting NCT04613986 - Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19 N/A
Recruiting NCT05447013 - Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients Phase 1/Phase 2
Completed NCT04733833 - A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 Phase 2
Recruiting NCT04712344 - Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO) Phase 2
Terminated NCT04713176 - Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients Phase 3
Recruiting NCT04648410 - Corticosteroids in Severe COVID-19(ASAP-C Study)
Recruiting NCT05254990 - Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia Phase 3
Completed NCT05596617 - Safety and Efficacy of Medications COVID-19 N/A